Predictive Oncology (POAI, Financial) has achieved notable advancements in the realm of biomarker discovery, drug discovery, and the repurposing of medications. These strides are part of the company’s strategic plan to integrate its proprietary biomarker identification system with advanced AI screening technologies.
Utilizing a combination of active machine learning and a comprehensive biobank of dissociated tumor cells derived from patients, Predictive Oncology is pioneering an innovative approach to repurpose discontinued oncology drugs. This method not only identifies new potential uses for these drugs but also offers a sustainable commercial model.
Through a meticulously curated selection of previously abandoned drugs, the company's AI-driven screening method has pinpointed three compounds that show promise for further evaluation in cancer treatments that have not been explored before. According to Dr. Arlette Uihlein, Senior Vice President of Translational Medicine and Drug Discovery at Predictive Oncology, the company has effectively demonstrated its capability to leverage machine learning and patient tumor samples to capture diverse patient responses in under three months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Predictive Oncology Inc (POAI, Financial) is $3.00 with a high estimate of $3.00 and a low estimate of $3.00. The average target implies an upside of 212.50% from the current price of $0.96. More detailed estimate data can be found on the Predictive Oncology Inc (POAI) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Predictive Oncology Inc's (POAI, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Predictive Oncology Inc (POAI, Financial) in one year is $2.23, suggesting a upside of 132.29% from the current price of $0.96. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Predictive Oncology Inc (POAI) Summary page.
